Scarica l'app Stockscreener
53.60
1.63%
0.86
Dopo l'orario di chiusura:
53.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Precedente Chiudi:
$52.74
Aprire:
$52.28
Volume 24 ore:
1.64M
Relative Volume:
2.18
Capitalizzazione di mercato:
$4.97B
Reddito:
$4.72M
Utile/perdita netta:
$-277.91M
Rapporto P/E:
-15.72
EPS:
-3.41
Flusso di cassa netto:
$-203.56M
1 W Prestazione:
-0.11%
1M Prestazione:
-4.41%
6M Prestazione:
+21.24%
1 anno Prestazione:
+55.41%
Intervallo 1D:
$51.73
$54.25
Intervallo di 1 settimana:
$50.81
$56.15
Portata 52W:
$33.67
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Nome
Crinetics Pharmaceuticals Inc
Settore
Industria
Telefono
858-450-6464
Indirizzo
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Confronta CRNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
53.60 | 4.97B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-01-16 | Iniziato | Morgan Stanley | Overweight |
| 2023-12-21 | Iniziato | Jefferies | Hold |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Iniziato | Oppenheimer | Outperform |
| 2023-04-24 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-23 | Iniziato | Evercore ISI | Outperform |
| 2021-06-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Iniziato | ROTH Capital | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-13 | Iniziato | JP Morgan | Neutral |
| 2018-08-13 | Iniziato | Leerink Partners | Outperform |
| 2018-08-13 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Geode Capital Management LLC - MarketBeat
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook - Investing.com
(CRNX) Trading Advice - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given Market Outperform Rating at JMP Securities - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Franklin Resources Inc. - MarketBeat
Barclays PLC Acquires 89,358 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest Update - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer - Investing.com India
Acromegaly Pipeline Trends 2024: Clinical Trials, Therapeutic - openPR
Isabel Kalofonos Joins Crinetics Pharmaceuticals as Chief Commercial Officer - citybiz
Crinetics appoints Isabel Kalofonos as CCO - TipRanks
JMP Securities Reaffirms Market Outperform Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) - MarketBeat
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Benzinga
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer - The Manila Times
Crinetics Pharma Strengthens Commercial Leadership, Names Veteran Launch Expert as Chief Commercial Officer - StockTitan
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Australia
Lord Abbett & CO. LLC Decreases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
State Street Corp Purchases 25,561 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
BNP Paribas Financial Markets Boosts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Crinetics Pharmaceuticals Awards Stock Options to New Talent in Strategic Expansion Move - StockTitan
Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly - Marketscreener.com
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly - The Manila Times
Crinetics' Breakthrough Oral Acromegaly Drug Advances as FDA Accepts NDA for First-in-Class Treatment - StockTitan
Wellington Management Group LLP Sells 160,722 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $70.18 Average Target Price from Analysts - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
73,340 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Bought by Castleark Management LLC - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $13.89 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Certain Stock Option of Crinetics Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 8-DEC-2024. - Marketscreener.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Janus Henderson Group PLC - MarketBeat
Parkman Healthcare Partners LLC Sells 63,752 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Raised by Charles Schwab Investment Management Inc. - MarketBeat
Cinctive Capital Management LP Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Fmr LLC - MarketBeat
Martingale Asset Management L P Purchases New Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (FRA:6Z4) EPS (Diluted) : €-3.42 (TTM As of Sep. 2024) - GuruFocus.com
Vestal Point Capital LP Makes New $10.48 Million Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Intech Investment Management LLC Purchases New Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Fisher Asset Management LLC Acquires 37,429 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Congenital Hyperinsulinism Pipeline 2024: Clinical Trials - openPR
Natixis Advisors LLC Purchases 11,870 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Lowers Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Principal Financial Group Inc. Acquires 64,504 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals' SWOT analysis: biotech stock poised for growth with rich pipeline - Investing.com
Jennison Associates LLC Acquires 13,470 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Victory Capital Management Inc. Has $17.55 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
First Turn Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for CRNX Earnings - MarketBeat
Learn to Evaluate (CRNX) using the Charts - Stock Traders Daily
Crinetics Pharmaceuticals Inc Azioni (CRNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Crinetics Pharmaceuticals Inc Azioni (CRNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Struthers Richard Scott | President & CEO |
Dec 02 '24 |
Sale |
57.57 |
10,000 |
575,700 |
100,000 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):